Thyroxine therapy in euthyroid patients does not affect body composition or muscular function

Thyroid

Volumn 18, Issue 1, 2008, Pages 13-19

  Dubois, Séverine ^a   Abraham, Pierre ^a   Rohmer, Vincent ^a,b   Rodien, Patrice ^a,b   Audran, Maurice ^a,b   Dumas, Jean François ^b   Ritz, Patrick ^a,b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; THYROTROPIN; THYROXINE;

ADULT; ANTHROPOMETRY; ARTICLE; BIOENERGY; BODY COMPOSITION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY EXPENDITURE; ENERGY METABOLISM; ERGOMETRY; EUTHYROIDISM; EXERCISE TEST; FEMALE; FOLLOW UP; HEART RATE; HORMONAL THERAPY; HUMAN; IMPEDANCE; LUNG GAS EXCHANGE; MORNING DOSAGE; MUSCLE FUNCTION; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REST; SINGLE DRUG DOSE; SKINFOLD THICKNESS; THYROID NODULE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; BODY COMPOSITION; ENERGY METABOLISM; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MIDDLE AGED; MUSCLE, SKELETAL; PROSPECTIVE STUDIES; THYROID NODULE; THYROXINE;

EID: 38649091735     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0037     Document Type: Article

References (53)

1. Astwood EB, Cassidy CE, Aurbach GD 1960 Treatment of goiter and thyroid nodules with thyroid. JAMA 174:459-464.
2. La Rosa GL, Lupo L, Giuffrida D, Gullo D, Vigneri R, Belfiore A1995 Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid. Ann Intern Med 122:1-8.
3. Mainini E, Martinelli I, Morandi G, Villa S, Stefani I, Mazzi C 1995 Levothyroxine suppressive therapy for solitary thyroid nodule. J Endocrinol Invest 18:796-799.
4. Wémeau JL, Caron P, Schvartz C, Schlienger JL, Orgiazzi J, Cousty C, Vlaeminck-Guillem V 2002 Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French thyroid research group. J Clin Endocrinol Metab 87:4928-4934.
5. Gharib H, James EM, Charbonneau JW, Naessens JM, Offord KP, Gorman CA 1987 Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study. N Engl J Med 317:70-75.
6. Papini E, Bacci V, Panunzi C, Pacella CM, Fabbrini R, Bizzarri G, Petrucci L, Giammarco V, La Medica P, Masala M 1993 A prospective randomized trial of levothyroxine suppressive therapy for solitary thyroid nodules. Clin Endocrinol (Oxf ) 38:507-513.
7. Reverter JL, Lucas A, Salinas I, Audi L, Foz M, Sanmarti A 1992 Suppressive therapy with levothyroxine for solitary thyroid nodules. Clin Endocrinol (Oxf ) 36:25-28.
8. Zelmanovitz F, Genro S, Gross JL 1998 Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab 83:3881-3885.
9. Castro MR, Carabello PJ, Morris JC 2002 Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. J Clin Endocrinol Metab 87:4154-4159.
10. Sdano MT, Falcigia M, Welge JA, Steward DL 2005 Efficacy of thyroid hormone suppression for benign thyroid nodules: meta-analysis of randomized trials. Otolaryngol Head Neck Surg 133:391-396.
11. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazaferri EL, McIver B, Sherman SI, Tuttle RM; the American Thyroid Association Guidelines Taskforce 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142.
12. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY 1996 Effects on bone mass of long-term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 81:4278-4289.
13. Appetecchia M 2005 Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort of women study. Horm Res 64:293-298.
14. Reverter JL, Holgado S, Alonso N, Salinas I, Granada ML, Sanmarti A 2005 Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. Endocr Relat Cancer 12:973-981.
15. Quan ML, Pasieka JL, RorstadO2002 Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J Surg Oncol 79:62-69.
16. Bauer M, Fairbanks L, Berghofer A, Hierholzer J, Bschor T, Baethge C, Rasgon N, Sasse J, Whybrom PC 2004 Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study. J Affect Disord 83:183-190.
17. Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, Pigliaru F, Mariotti S 2000 Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab 85:159-164.
18. Shapiro LE, Sievert R, Ong L, Ocampo EL, Chance RA, Lee M, Nanna M, Ferrick K, Surks MI 1997 Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of levothyroxine. J Clin Endocrinol Metab 82:2592-2595.
19. Sawin C, Geller A, Wolf P, Belanger AJ, Baker E, Bacharach P, Wilson P, Benjamin E, D'Agostino R 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331:1249-1252.
20. Olson BR, Klein I, Benner R, Burdett R, Trzepacz P, Levey GS 1991 Hyperthyroid myopathy and the response to treatment. Thyroid 1:137-141.
21. Brennan MD, Powell C, Kaufman KR, Sun PC, Bahn RS, Nair KS 2006 The impact of overt and subclinical hyperthyroidism on skeletal muscle. Thyroid 16:375-376.
22. Ritz P, Dumas JF, Salle A, Simard G, Malthiery Y, Rohmer V 2002 Thyroid hormones and obesity. Ann Endocrinol (Paris) 63:135-139.
23. Lanni A, Moreno M, Lombardi A, de Lange P, Goglia F 2001 Control of energy metabolism by iodothyronines. J Endocrinol Invest 24:897-913.
24. Durnin JV, Womersley J 1974 Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 32:77-97.
25. Wang W, Wang Z, Faith MS, Kotler D, Shih R, Heymsfield SB 1999 Regional skeletal muscle measurement: evaluation of new dual-energy X-ray absorptiometry model. J Appl Physiol 87:1163-1177.
26. Levine JA, Abboud L, Barry M, Reed JE, Sheedy PF, Jensen MD 2000 Measuring leg muscle and fat mass in humans: comparison of CT and dual-energy X-ray absorptiometry. J Appl Physiol 88:452-456.
27. Heymsfield SB, Smith R, Aulet M, Bensen B, Lichtman S, Wang J 1999 Validity of fan-beam dual-energy X-ray absorptiometry for measuring fat-free mass and leg muscle mass. J Appl Physiol 87:1513-1520.
28. Segal KR, Burastero S, Chun A, Coronel P, Pierson RN, Jr., Wang J 1991 Estimation of extracellular and total body water by multiple-frequency bioelectrical impedance measurement. Am J Clin Nutr 54:26-29.
29. Wasserman K 1994 Measurements during integrative cardiopulmonary exercise. In: Principles of Exercise Testing and Interpretation. Fourth edition. Lea and Febiger, Philadelphia. p52.
30. Wolf M, Weigert A, Kreyman G 1996 Body composition and energy expenditure in thyroidectomized patients during short-term hypothyroidism and thyrotropin suppressive therapy. Eur J Endocrinol 134:168-173.
31. Lovejoy JC, Smith SR, Bray GA, Veldhuis JD, Rood JC, Tulley R 1997 A paradigm of experimentally induced mild hyperthyroidism: effects on nitrogen balance, body composition, and energy expenditure in healthy young women. J Clin Endocrinol Metab 82:765-770.
32. Langdahl BL, Loft AG, Eriksen EF, Mosekide L, Charles P 1996 Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. Thyroid 6:161-168.
33. Lonn L, Stenlof K, Ottosson M, Lindroos AK, Nystrom E, Sjostrom E 1998 Body weight and body composition changes after treatment of hyperthyroidism. J Clin Endocrinol Metab 83:4269-4273.
34. Ritz P 2000 The physiology of aging, with respect to system changes (circulatory, gastrointestinal, neuroendocrine, and immune) and their significance for energy and protein metabolism. Eur J Clin Nutr 54:21-25.
35. Horber FF, Gruber B, Thomi F, Jensen EX, Jeager P 1997 Effects of sex and age on bone mass, body composition, and fuel metabolism in humans. Nutrition 13:524-534.
36. Gong DW, Monemdjou S, Gavrilova O, Leon LR, Marcus-Samuels B, Chou CJ, Everett C, Kozak LP, Li C, Deng C, Harper ME, Reitman ML 2000 Lack of obesity and normal response to fasting and thyroid hormone in mice lacking uncoupling protein-3. J Biol Chem 275:16251-16257.
37. Barbe P, Larrouy D, Boulanger C, Chevilotte E, Viguerie N, Thalamas C, Oliva Trastoy M, Roques M, Vidal H, Langin D 2001 Triiodothyronine-mediated up-regulation of UCP2 and UCP3 mRNA expression in human skeletal muscle without coordinated induction of mitochondrial respiratory chain genes. FASEB J 15:13-15
38. Boivin M, Camirand A, Carli F, Hoffer LJ, Silva JE 2000 Uncoupling protein-2 and -3 messenger ribonucleic acids in adipose tissue and skeletal muscle of healthy males: variability, factors affecting expression, and relation to measures of metabolic rate. J Clin Endocrinol Metab 85:1975-1983.
39. Wiesner RJ, Kurowski TT, Zak R 1992 Regulation by thyroid hormone of nuclear and mitochondrial genes encoding subunits of cytochrome-c oxidase in rat liver and skeletal muscle. Mol Endocrinol 6:1458-1467.
40. Short KR, Nygren J, Barazzoni R, Levine J, Nair KS 2001 T(3) increases mitochondrial ATP production in oxidative muscle despite increased expression of UCP-2 and -3. Am J Physiol Endocrinol Metab 280:761-769.
41. Lanni A, Moreno M, Cioffi M, Goglia F 1992 Effect of 3,3′- diiodothyronine and 3,5-diiodothyronine on rat liver oxidative capacity. Mol Cell Endocrinol 86:143-148.
42. Lanni A, Moreno M, Cioffi M, Goglia F 1993 Effect of 3,3′- diiodothyronine and 3,5-diiodothyronine on rat liver mitochondria. J Endocrinol 136:59-64.
43. Al Adsani H, Hoffer LJ, Enrique Silva J 1997 Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab 82:1118-1125.
44. Duyff RF, Van den Bosch J, Laman DM, Potter Van Loon BJ, Linssen Wim HJP 2000 Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry 68:750-755.
45. Ramsay ID 1966 Muscle dysfunction in hyperthyroidism. Lancet 2:931-932.
46. Martin WH 3rd, Spina RJ, Korte E, Yarasheski KE, Angelopoulos TJ, Nemeth PM, Saffitz JE 1991 Mechanisms of impaired exercise capacity in short duration experimental hyperthyroidism. J Clin Invest 88:2047-2053.
47. Norrelund H, Hove KY, Brems-Dalgaard E, Jurik AG, Nielsen LP, Nielsen S, Jorgensen JO, Weeke J, Moller N 1999 Muscle mass and function in thyrotoxic patients before and during medical treatment. Clin Endocrinol 51:639-699.
48. Wiles CM, Young A, Jones DA, Edwards RH 1979 Muscle relaxation rate, fibre-type composition and energy turnover in hyper- and hypothyroid patients. Clin Sci 57:375-384.
49. Caiozzo VJ, Swoap S, Tao M, Menzel D, Baldwin KM 1993 Single fiber analyses of type IIA myosin heavy chain distribution in hyper- and hypothyroid soleus. Am J Physiol 265:C842-C850.
50. Zürcher RM, Horber FH, Grünig BE, Frey FJ 1989 Effect of thyroid dysfunction on thigh muscle efficiency. J Clin Endocrinol Metab 69:1082-1086.
51. Da Nobrega AC, Vaisman M, De Araujo CG 1997 Skeletal muscle function and body composition of patients with hyperthyroidism. Med Sci Sports Exerc 29:175-180.
52. Erkintalo M, Bendahan D, Mattei JP, Fabreguettes C, Vague P, Cozzone PJ 1998 Reduced metabolic efficiency of skeletal muscle energetics in hyperthyroid patients evidenced quantitatively by in vivo phosphorus-31 magnetic resonance spectroscopy. Metabolism 47:769-776.
53. Martin WH 3rd 1993 Triiodothyronine, beta-adrenergic receptors, agonist responses and exercise capacity. Ann Thorac Surg 56:S24-S34.